Complications

Complication
Timeframe
Likelihood
long term
high

The incidence of osteoporotic hip fractures is increasing; osteoporotic hip fractures are associated with significant disability and reduced quality of life.[205]

After fracture, pharmacological treatment is indicated. Fall-prevention measures remain important. In the US, mortality is 20% in the first year after a hip fracture and institutionalisation for long-term care is about 20%. Approximately two-thirds of people do not return to their prior level of function after a hip fracture.[3]

Hip fractures

long term
high

Rib fractures are common among older women with osteoporosis.[206]

Rib fractures

long term
medium

Osteoporosis is associated with a 2.4-fold increase in wrist fracture risk in people aged ≥50 years.[207] Prior wrist fracture is a strong predictor of future osteoporotic fracture in postmenopausal women.[208]

Wrist fractures

long term
low

There is evidence to suggest that atypical subtrochanteric and femoral fractures are associated with long-term bisphosphonate use.[117][118][119] Atypical subtrochanteric and diaphysial femoral fractures may occur with prolonged bisphosphonate treatment with a median duration of 7 years. Major characteristics include spontaneous fractures without trauma, transverse or short oblique orientation, and medial spike when the fracture is complete. Minor characteristics include cortical thickening; periosteal reaction of the lateral cortex; and concomitant use of other antiresorptive drugs, glucocorticoids, or proton-pump inhibitors. In 50% of individuals, fracture is preceded by thigh or inguinal pain.

variable
medium

Osteoporosis with fractures is a common cause of chronic pain in older people.

variable
medium

Because of its oestrogenic effects, raloxifene increases the risk of blood clots, including deep vein thrombosis.[177]​ The greatest increase in risk occurs during the first 4 months of use.[209]

variable
low

Because of its oestrogenic effects, raloxifene increases the risk of blood clots, including pulmonary embolism.[177]​ The greatest increase in risk occurs during the first 4 months of use.[209]

variable
low

There is evidence to suggest that atypical osteonecrosis of the jaw is associated with long-term bisphosphonate use.[118][210]​ Jaw necrosis occurs specifically in those patients receiving intravenous bisphosphonate treatment who have poor dental hygiene or following dental extractions, dental implants, and/or root canal work.

Use of this content is subject to our disclaimer